Several drugs may increase blood prolactin concentration. Dopamine receptor antagonists are one of the most common causes of hyperprolactinemia. To reduce happening of hyperprolactinemia, some medicinal plants have been traditionally used. This review focuses on the efficacy of effective herbal medicines in the management of human drug-induced hyperprolactinemia. PubMed, Scopus, Web of science, Cochrane library database were searched for any relevant studies that investigated the effect of herbal medicines on drug induced hyperprolactinemia up to May 2010. The inclusion criteria were clinical trials studied efficacy of herbal medicines in drug-induced hyperprolactinemia. Among different compounds, four herbal supplements including Shakuyaku-kanzo-to (TJ-68), Peony-Glycyrrhiza Decoction (PGD), Zhuangyang capsule, Tongdatang serial recipe (TDT) were found clinically effective and safe in management of drug-induced hyperprolactinemia. Although, the quality of included clinical trials was low not allowing us to conduct a meta-analysis but positive results on efficacy (TJ-68), (PGD), Zhuangyang capsule and (TDT) cannot be ignored. Interestingly compounds with prolactin-suppressive effects have a number of diterpenes mainly clerodadienols that seem almost identical for their efficacy. Further studies to isolate and characterize constituents of the effective herbs are needed to reach novel therapeutic and more effective agents.
How to cite this article:
S. Hasani- Ranjbar, H. Vahidi, S. Taslimi, N. Karimi, B. Larijani and M. Abdollahi, 2010. A Systematic Review on the Efficacy of Herbal Medicines in the Management of Human Drug-induced Hyperprolactinemia; Potential Sources for the Development of Novel Drugs. International Journal of Pharmacology, 6: 691-695.
Any process interfering with dopamine synthesis, its transport to the pituitary gland, or its action at the level of lactotroph dopamine receptors can cause hyperprolactinemia (Mancini et al., 2008). Hyperprolactinemia is mostly seen in women, but also observed in men and even in adolescence and childhood (Patel and Bamigboye, 2007). Hyperprolactinemia is a common endocrinological disorder that is caused by many physiological or pathological conditions (Torre and Falorni, 2007). Women with oligomenorrhea, amenorrhea, or galactorrhea and men with symptoms of hypogonadism or impotence or infertility should be checked for blood prolactin to determine pharmacologic or extrapituitary causes of hyperprolactinemia and neuroradiologic evaluation of the hypothalamic-pituitary region (Casanueva et al., 2006).
Several drugs may cause a significant increase in blood prolactin concentration (Torre and Falorni, 2007) which dopamine D2 receptor antagonists are the main. These include antipsychotic drugs such as risperidone, phenothiazines, haloperidol (David et al., 2000), butyrophenones (Rivera et al., 1976), metoclopramide (McCallum et al., 1976) and domperidone (Sowers et al., 1982). These drugs can be categorized for their potency to the pituitary dopamine receptors that is in correlation with their prolactin release, as follows: sulpiride>risperidone>haloperidol> olanzapine>clozapine (David et al., 2000; Markianos et al., 2001). The high prevalence of psychotic disorders (Perala et al., 2007) and the need for long-term therapy makes antipsychotic adverse effects, such as hyperprolactinemia, a major problem. In patients taking neuroleptic medications, drug-induced hyperprolactinemia should be confirmed with temporary drug withdrawal or pituitary Magnetic Resonance Imaging (MRI). Dopamine agonist drugs like bromocriptine, cabergoline, pergolide and quinagolide are usually the first choice for controlling of hyperprolactinemia but they have gastrointestinal, cardiovascular and neurological adverse effects (Vance et al., 1984; Gillam et al., 2006). Of course, for treatment of drug-induced hyperprolactinemia, combined use of dopamine antagonists and dopamine agonists is not advised because of increased risk of side effects (Perovich et al., 1989; Tollin, 2000).
To best of present knowledge, there is no review on the use of herbal medicines in the management of drug-induced hyperprolactinemia. Thus, in the present study, we systematically reviewed all existing data on the efficacy of herbal medicines in the management of drug-induced hyperprolactinemia in human.
MATERIALS AND METHODS
PubMed, Scopus, Web of science, Cochrane library database were searched for any relevant studies that investigated the effect of herbal medicines on hyperprolactinemia up to May 2010. The search terms were: prolactin, hyperprolactinemia, prolactinoma, galactorrhea and herb, herbal medicine, plant, traditional medicine and antipsychotics, neuroleptic, schizophrenia and human.
The quality of trials was assessed by Jadad score for characterizing studies according to appropriate randomization, blinding and description of study withdrawals or dropouts (Moher et al., 1995). The description of this score is as follows:
|•||Whether randomized (Yes = 1 point, No = 0)|
|•||Whether randomization was described appropriately (Yes = 1 point, No = 0)|
|•||Double-blind (Yes = 1 point, No = 0)|
|•||Was the double-blinding described appropriately (Yes = 1 point, No = 0)|
|•||Whether withdrawals and dropouts were described (Yes = 1 point, No = 0).|
The quality score ranges from 0 to 5 points; a low-quality report score is = 2 and a high-quality report score is at least 3.
Three reviewers evaluated studies by reading the title and abstract of the search results to eliminate duplicates, reviews, case studies and letters. The inclusion criteria were clinical trials studied efficacy of herbal medicines in drug-induced hyperprolactinemia.
RESULTS AND DISCUSSION
After searching databases, 48 results were found which only 6 of them were appropriate for inclusion. Four were written in English and 2 in Chinese languages. Full text of 3 English articles and abstract of the 2 Chinese articles were studied. Data were extracted and shown in the Table 1. Four herbal supplements including Shakuyaku-kanzo-to (TJ-68), Peony-Glycyrrhiza Decoction (PGD), Zhuangyang capsule, Tongdatang serial recipe (TDT) were found clinically effective and safe in management of drug-induced hyperprolactinemia.
All of the studies showed a significant decrease in blood prolactin level. In the first trial, the prolactin levels decreased by more than 50% with Shakuyaku-kanzo-to (TJ-68) treatment among 5 patients. Plasma prolactin level at 8 weeks was not significantly different with the baseline. Three of 10 patients, who had complained of reduced sexual desire, experienced subjective improvement (Yamada et al., 1997). In the second trial, decreased plasma prolactin level was observed in nine patients treated with TJ-68 and in four, the plasma prolactin decreased more than 50%. Subjective improvement of reduced sexual desire was observed in three patients at 4 weeks (Yamada et al., 1996).Yamada has reported a case with risperidone-induced amenorrhea and demonstrated TJ-68 to be effective in correcting neuroleptic-induced amenorrhea and hyperprolactinemia (Yamada et al., 1999). The exact mechanism of TJ-68 is unknown although it may have a direct inhibitory effect on prolactin release from pituitary (Yamada et al., 1996, 1997). It also decreased estradiol in rats and this reduction might decrease prolactin levels.In the third trial, both Peony-Glycyrrhiza Decoction (PGD) and bromocriptine treatment had a similar percentage of amplitude of the decrease in blood prolactin. Nevertheless, unlike bromocriptine therapy, the herbal remedy did not cause worsening of psychotic symptoms, either transiently or individually. Conversely, a significant greater proportion of patients (nearly 56%) showed improvements on adverse effects related to hyperprolactinemia during PGD treatment (Yuan et al., 2008). The PGD with multiple contents including albifloran, paenoiflorin, benzoylpaeoiflorin, liquiritin and glycyrrhetinic acid had putative mechanisms and multiple actions deserves needed to be further investigated.
In the fourth trial, after 8 weeks of treatment with either Zhuangyang capsule (n = 39) or placebo capsule (n = 37) supplemented to risperidone, the serum level of prolactin decreased significantly, while in the control group, the prolactin markedly increased.
|Table 1:||Human studies considering herbal medicines for treatment of drug-induced hyperprolactinemia|
|BMT: Bromocriptine; PRL: Prolactin; RCT: Randomized control trial; GAS: Galactorrhea-amenorrhea syndrome|
There was a significant difference (decreased 26.51 ng mL-1 vs increased 15.56 ng mL-1) in improvement of serum prolactin in trial group compared with that of control group. This effect of Zhuangyang capsule was not different between male and female groups (Chen et al., 2008).
In the fifth trial, serum prolactin reduced in the group treated with Tongdatang serial recipe (TDT) significantly more than that of control group (Ding et al., 2008). From 49 patients of the treatment group, 31 patients got cure (63.3%).
The first two studies did not have control group and were done only in men. Instead, the third and the fifth ones were done in women, based on the fact that the incidence of events associated with hyperprolactinemia is much higher and more severe in women (Yuan et al., 2008).
There are some other herbal medicines which are useful in treatment of hyperprolactinemia, such as Vitexagnus castus (Wuttke et al., 2003) but they are not studied on antipsychotic-induced hyperprolactinemia. The search for chemical identity of the dopaminergic compounds resulted in isolation of a number of diterpenes of which some clerodadienols were most important for the prolactin-suppressive effects. They were almost identical in their prolactin-suppressive properties than dopamine itself.
Although, the quality of included clinical trials was low that is a limitation of this review not allowing us to conduct a meta-analysis but positive results on efficacy and safety of Shakuyaku-kanzo-to (TJ-68), Peony-Glycyrrhiza Decoction (PGD), Zhuangyang capsule and Tongdatang serial recipe (TDT) cannot be ignored. As herbal medicines produce definite therapeutic effects with few side effects, in the recent years, many traditionally-used remedies have found evidenced-based places in novel medicine in various diseases like diabetes (Rahimi et al., 2010, 2005; Hasani-Ranjbar et al., 2008, 2010), obesity (Hasani-Ranjbar et al., 2009a), oxidant- and age-related diseases (Hasani-Ranjbar et al., 2009b), colitis (Rahimi et al., 2009), pancreatitis (Mohseni-Salehi-Monfared et al., 2009a), islet transplantation (Mohseni-Salehi-Monfared et al., 2009b), bone health and osteoporosis (Salari et al., 2008) and multi-organ benefits (Momtaz and Abdollahi, 2010) making the present report worthy. Further studies on isolation and characterization of their constituents would open a new approach for novel therapeutic and more effective agents.
This study is the outcome of an in-house study and has not been supported financially.
Casanueva, F.F., M.E. Molitch, J.A. Schlechte, R. Abs and V. Bonert et al., 2006. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf.), 65: 265-273.
Chen, Z., G. Wang, X. Wang, L. Li and D. Xiao, 2008. Effects of Zhuangyang capsules on the serum prolactin of schizophrenic patients treated with risperidone. Med. J. Wuhan Univ., 29: 798-800.
David, S.R., C.C. Taylor, B.J. Kinon and A. Breier, 2000. The effects of olanzapine, rispiridone and haloperiodol on plasma prolactin levels in patients with schizophrenia. Clin. Ther., 22: 1085-1096.
Ding, Y., H.Z. Qian and Y.Q. Wang, 2008. Effect of tongdatang serial recipe on antipsychotic drug-induced galactorrhea-amenorrhea syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi, 28: 263-265, (In Chinese).
Gillam, M.P., M.E. Molitch, G. Lombardi and A. Colao, 2006. Advances in the treatment of prolactinomas. Endocrine Rev., 27: 485-534.
Hasani-Ranjbar, S., B. Larijani and M. Abdollahi, 2008. A systematic review of Iranian medicinal plants useful in diabetes mellitus. Arch. Med. Sci., 4, 3: 285-292.
Hasani-Ranjbar, S., B. Larijani and M. Abdollahi, 2009. A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflamm. Allergy Drug Targets, 8: 2-10.
Hasani-Ranjbar, S., N. Nayebi, B. Larijani and M. Abdollahi, 2009. A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity. World J. Gastroenterol., 15: 3073-3085.
Hasani-Ranjbar, S., N. Nayebi, B. Larijani and M. Abdollahi, 2010. A systematic review of the efficacy and safety of Teucrium species; from anti-oxidant to anti-diabetic effects. Int. J. Pharmacol., 6: 315-325.
Mancini, T., F.F. Casanueva and A. Giustina, 2008. Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. North Am., 37: 67-99.
Markianos, M., J. Hatzimanolis and L. Lykouras, 2001. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur. Arch. Psychiatry Clin. Neurosci., 251: 141-146.
McCallum,J.R., R.W., Sowers, J.M. Hershman and R.A.L. Sturdevant, 1976. Metoclopramide stimulates prolactin secretion in man. J. Clin. Endocrinol. Metab., 42: 1148-1152.
Moher, D., A.R. Jadad, G. Nichol, M. Penman, P. Tugwell and S. Walsh, 1995. Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists. Controlled Clin. Trials, 16: 62-73.
Mohseni-Salehi-Monfared, S.S., H. Vahidi, A.H. Abdolghaffari, S. Nikfar and M. Abdollahi, 2009. Antioxidant therapy in the management of acute, chronic and post-ERCP pancreatitis: A systematic review. World J. Gastroenterol., 15: 4481-4490.
Momtaz, S. and M. Abdollahi, 2010. An update on pharmacology of Satureja species; From antioxidant, antimicrobial, antidiabetes and anti-hyperlipidemic to reproductive stimulation. Int. J. Pharmacol., 6: 346-353.
Monfared, S.S.M.S., B. Larijani and M. Abdollahi, 2009. Islet transplantation and antioxidant management: A systematic review. World J. Gastroenterol., 15: 1153-1161.
Patel, S.S. and V. Bamigboye, 2007. Hyperprolactinaemia. J. Obstet. Gynaecol., 27: 455-459.
Perala, J., J. Suvisaari, S.I. Saarni, K. Kuoppasalmi and E. Isometsa et al., 2007. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry, 64: 19-28.
Perovich, R.M., J.A. Lieberman, W.W. Fleischhacker and J. Alvir, 1989. The behavioral toxicity of bromocriptine in patients with psychiatric illness. J. Clin. Psychopharmacol., 9: 417-422.
Rahimi, R., S. Ghiasi, H. Azimi, S. Fakhari and M. Abdollahi, 2010. A review of the herbal phosphodiesterase inhibitors: Future perspective of new drugs. Cytokine, 49: 123-129.
Rahimi, R., S. Mozaffari and M. Abdollahi, 2009. On the use of herbal medicines in management of inflammatory bowel diseases: A systematic review of animal and human studies. Dig. Dis. Sci., 54: 471-480.
Rahimi, R., S. Nikfar, B. Larijani and M. Abdollahi, 2005. A review on the role of antioxidants in the management of diabetes and its complications. Biomed. Pharmacother., 59: 365-373.
Rivera, J.L., S. Lal, P. Ettigi, S. Hontela, H.F. Muller and H.G. Friesen, 1976. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin. Endocrinol., 5: 273-282.
Salari, P., A. Rezaie, B. Larijani and M. Abdollahi, 2008. A systematic review of the impact of n‐3 fatty acids in bone health and osteoporosis. Med. Sci. Monitor, 14: RA37-44.
Sowers, J.R., B. Sharp and R.W. McCallum, 1982. Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man. J. Clin. Endocrinol. Metab., 54: 869-871.
Tollin, S.R., 2000. Use of the dopamine agonistsbromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J. Endocrinol. Invest., 23: 765-770.
Torre, D.L. and A. Falorni, 2007. Pharmacological causes of hyperprolactinemia. Ther. Clin. Risk Manage., 3: 929-951.
Vance, M.L., W.S. Evans and M.O. Thorner, 1984. Drugs five years later. Bromocriptine. Ann. Intern. Med., 100: 78-91.
Wuttke, W., H. Jarry, V. Christoffel, B. Spengler and D. Seidlova-Wuttke, 2003. Chaste tree (Vitexagnus-castus)--pharmacology and clinical indications. Phytomedicine, 10: 348-357.
Yamada, K., G. Yagi and M. Asai, 1999. Herbal medicine (Shakuyaku-kanzo-to) in the treatment of risperidone-induced amenorrhea. J. Clin. Psychopharmacol., 19: 380-381.
Yamada, K., S. Kanba, G. Yagi and M. Asai, 1997. Effectiveness of herbal medicine (shakuyaku-kanzo-to) for neuroleptic-induced hyperprolactinemia. J. Clin. Psychopharmacol., 17: 234-235.
Yamada, K., S. Kanba, T. Murata, M. Fukuzawa, B. Terashi, G. Yagi and M. Asai, 1996. Effectiveness of shakuyaku-kanzo-to in neuroleptic-induced hyperprolactinemia: A preliminary report. Psychiatry Clin. Neurosci., 50: 341-342.
Yuan, H.N., C.Y. Wang, C.W. Sze, Y. Tong and Q.R. Tan et al., 2008. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J. Clin. Psychopharmacol., 28: 264-270.